Ebook Nanomedicine for inflammatory diseases: Part 2
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: Ebook Nanomedicine for inflammatory diseases: Part 2
Ebook Nanomedicine for inflammatory diseases: Part 2
CHAPTER SIX.ONEThe Biology and Clinical Treatment of Multiple SclerosisMahsa Khayat-Khoei, Leorah Freeman, and John LincolnCONTENTS6.1.1Overview, Risk Ebook Nanomedicine for inflammatory diseases: Part 2k Factors, and Diagnosis of MS / 1726.1.1.1Epidemiology /1726.1.1.1.1Genetics / 1726.1.1.1.2Epigenetics and (he Environment / 1726.1.1.2Diagnosis of Multiple Sclerosis / 1736.1.1.2.1Clinical Features / 1736.1.1.2.2Magnetic Resonance Imaging / 1736.1.1.3Evolution and Prognosis / 1756.1.1.3.1Clinical Ebook Nanomedicine for inflammatory diseases: Part 2Phenotypes / 1756.1.1.3.2Prognosis and Prediction / 1756.1.2Pathophysiology of MS / 1766.1.2.1Adaptive Immune Response / 1766.1.2.2Innate Immune RespoEbook Nanomedicine for inflammatory diseases: Part 2
nse / 1776.1.2.2.1Astrocytes / 1776.1.2.2.2Microglia / 1786.1.2.3Focal Demyelination, Inflammation, and Neurodegeneration / 1786.1.2.3.1Evaluating WM CHAPTER SIX.ONEThe Biology and Clinical Treatment of Multiple SclerosisMahsa Khayat-Khoei, Leorah Freeman, and John LincolnCONTENTS6.1.1Overview, Risk Ebook Nanomedicine for inflammatory diseases: Part 2icles / 1806.1.2.6.2Mitochondrial Dysfunction / 1816.1.2.6.3Cerebral Perfusion / 1816.1.3Treatment Strategies in MS / 1816.1.3.1Overview of Treatments: Mechanisms of Action / 1816.1.3.2MS Phenotypes: Impact on Treatment Choice / 1836.1.4Future Goals / 1836.1.4.1Remyelinating Therapies / 1836.1.4.2Ne Ebook Nanomedicine for inflammatory diseases: Part 2uroprotection Strategies / 1846.1.5Conclusions / 184References /1841716.1.1OVERVIEW, RISK FACTORS, AND DIAGNOSIS OF MSCHAPTER SIX.ONEThe Biology and Clinical Treatment of Multiple SclerosisMahsa Khayat-Khoei, Leorah Freeman, and John LincolnCONTENTS6.1.1Overview, RiskCHAPTER SIX.ONEThe Biology and Clinical Treatment of Multiple SclerosisMahsa Khayat-Khoei, Leorah Freeman, and John LincolnCONTENTS6.1.1Overview, RiskGọi ngay
Chat zalo
Facebook